Abstract

BackgroundProstate cancer (CaP) is one of the most relevant causes of cancer death in Western Countries. Although detection of CaP at early curable stage is highly desirable, actual screening methods present limitations and new molecular approaches are needed. Gene expression analysis increases our knowledge about the biology of CaP and may render novel molecular tools, but the identification of accurate biomarkers for reliable molecular diagnosis is a real challenge. We describe here the diagnostic power of a novel 8-genes signature: ornithine decarboxylase (ODC), ornithine decarboxylase antizyme (OAZ), adenosylmethionine decarboxylase (AdoMetDC), spermidine/spermine N(1)-acetyltransferase (SSAT), histone H3 (H3), growth arrest specific gene (GAS1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Clusterin (CLU) in tumour detection/classification of human CaP.Methodology/Principal FindingsThe 8-gene signature was detected by retrotranscription real-time quantitative PCR (RT-qPCR) in frozen prostate surgical specimens obtained from 41 patients diagnosed with CaP and recommended to undergo radical prostatectomy (RP). No therapy was given to patients at any time before RP. The bio-bank used for the study consisted of 66 specimens: 44 were benign-CaP paired from the same patient. Thirty-five were classified as benign and 31 as CaP after final pathological examination. Only molecular data were used for classification of specimens. The Nearest Neighbour (NN) classifier was used in order to discriminate CaP from benign tissue. Validation of final results was obtained with 10-fold crossvalidation procedure. CaP versus benign specimens were discriminated with (80±5)% accuracy, (81±6)% sensitivity and (78±7)% specificity. The method also correctly classified 71% of patients with Gleason score<7 versus ≥7, an important predictor of final outcome.Conclusions/SignificanceThe method showed high sensitivity in a collection of specimens in which a significant portion of the total (13/31, equal to 42%) was considered CaP on the basis of having less than 15% of cancer cells. This result supports the notion of the “cancer field effect”, in which transformed cells extend beyond morphologically evident tumour. The molecular diagnosis method here described is objective and less subjected to human error. Although further confirmations are needed, this method posses the potential to enhance conventional diagnosis.

Highlights

  • Prostate cancer (CaP) is believed to become the most relevant cause of cancer death in the Western Countries in the near future because its incidence increases rapidly with age

  • The signature that we have identified is made of 4 metabolically related genes, ornithine decarboxylase (ODC), ornithine decarboxylase antizyme (OAZ), AdoMetDC, spermidine/spermine N(1)-acetyltransferase (SSAT), the regulatory genes of the polyamine metabolism, 2 genes related to cell cycle progression, H3 and GAS1, specific markers of S- and G0-phases, respectively [5,6], glyceraldehyde 3-phosphate dehydrogenase (GAPDH), an enzyme of the glycolitic pathway, and CLU an enigmatic protein whose biological role is still a matter of debate

  • Other successful studies resulted in molecular diagnosis of CaP, but they were only based on few selected, cancer-specific genes

Read more

Summary

Introduction

Prostate cancer (CaP) is believed to become the most relevant cause of cancer death in the Western Countries in the near future because its incidence increases rapidly with age. The diagnosis of CaP is conventionally obtained by saturation prostate biopsy and morphological examination of tissue sections. This method is reliable, but requires careful training. The ideal method should be fast, standardized and economically convenient Such achievement is possible in theory, but results published are not completely satisfactory yet, because they are usually based on a conventional approach with takes advantage of a single molecular predictor significantly up- or down-regulated in the cancer specimen versus benign control. Detection of CaP at early curable stage is highly desirable, actual screening methods present limitations and new molecular approaches are needed. We describe here the diagnostic power of a novel 8-genes signature: ornithine decarboxylase (ODC), ornithine decarboxylase antizyme (OAZ), adenosylmethionine decarboxylase (AdoMetDC), spermidine/spermine N(1)-acetyltransferase (SSAT), histone H3 (H3), growth arrest specific gene (GAS1), glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Clusterin (CLU) in tumour detection/classification of human CaP

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.